United Kingdom Vaccines Market Size, Share, and COVID-19 Impact Analysis, By Technology Type (Inactivated Vaccines, Toxoid Vaccines, Recombinant & Conjugate Vaccines, Live Attenuated Vaccines, and Others), By Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, and Others), By End User (Pediatric, Adults, and Travelers), and United Kingdom Vaccines Market Insights, Industry Trend, Forecasts to 2033

United Kingdom Vaccines Market Insights Forecasts to 2033

• The U.K. Vaccines Market Size Was Valued at USD 1.35 Billion in 2023.
• The U.K. Vaccines Market Size is Growing at a CAGR of 7.64% from 2023 to 2033
• The U.K. Vaccines Market Size is Expected to reach USD 2.82 Billion by 2033

The United Kingdom Vaccines Market Size is Anticipated to Exceed USD 2.82 Billion by 2033, Growing at a CAGR of 7.64% from 2023 to 2033. The growing number of vaccination programs, government initiatives, healthcare infrastructure, and advancement in vaccine technology are driving the growth of the vaccines market in the UK.     

Market Overview

The vaccines market refers to the market for biological preparations designed to provide immunity against specific diseases, having a crucial role in preventing infectious diseases and promoting public health. Vaccine is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease to prevent disease. They are administered via various routes, including injections and oral doses. Emphasis on the improvement in the process of vaccine development and innovation in formulations, storage, and distribution methods for enhancing effectiveness and streamlining delivery are escalating the vaccines market growth. There is a growing demand for vaccines due to increasing preference for vaccination initiatives and public health campaigns with the aid of government support, such as government-led immunization programs. Therapeutic vaccines offering corrective treatment for various conditions, including cancer, allergies, physiological disorders, and infectious diseases, are providing new market growth opportunities.

Report Coverage

This research report categorizes the market for the UK vaccines market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United Kingdom vaccines market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the UK vaccines market.

Driving Factors

The growing number of vaccination programs, including flu vaccination, BCG vaccination, COVID-19 vaccination, diphtheria, and many other vaccination programmes, are driving the market demand.  National RSV vaccination programme announced for protecting infants and elderly people in UK. Further, the advancement in the vaccine technology as well as the development of healthcare infrastructure, are promoting the market growth. For instance, In november 2024, Movianto expanded its active frozen transport solutions to support the 2024/25 vaccine and flu campaigns, widening its distribution and delivery capabilities.

 Restraining Factors

The increased costs associated with vaccine research, development, and distribution, especially for advanced vaccine technology, are challenging the market. Further, the lengthy regulatory processes and inequitable access are hindering market growth.

Market Segmentation

The United Kingdom vaccines market share is classified into technology type, indication, and end user. 

• The recombinant & conjugate vaccines segment dominated the UK vaccines market with the largest share in 2023 and is expected to grow at a significant CAGR during the projected period.

The United Kingdom vaccines market is segmented by technology type into inactivated vaccines, toxoid vaccines, recombinant & conjugate vaccines, live attenuated vaccines, and others. Among these, the recombinant & conjugate vaccines segment dominated the UK vaccines market with the largest share in 2023 and is expected to grow at a significant CAGR during the projected period. Recombinant & conjugate vaccines use only specific pieces of the germ, giving a very strong immune response to the targeted key part of the germ. The prevalence of infectious diseases and product approvals are contributing to driving the market.

• The human papilloma virus segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR growth during the projected period.

The United Kingdom vaccines market is segmented by indication into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, and others. Among these, the human papilloma virus segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR growth during the projected period. HPV is a viral illness and is the most common infection spread by complexion contact and even results in cancers of the uterus, anus, and neck. The implementation of HPV vaccinations in immunization schedules and awareness campaigns is propelling the market growth.

• The pediatric segment accounted for the largest share of the UK vaccines market in 2023 and is expected to grow at a significant CAGR growth during the projected period.

The United Kingdom vaccines market is segmented by end user into pediatric, adults, and travellers. Among these, the pediatric segment accounted for the largest share of the UK vaccines market in 2023 and is expected to grow at a significant CAGR growth during the projected period. The prevalence of chronic diseases among children necessitates the use of specialized vaccines. The growing travel medicine services, mandatory vaccination requirements, and health and safety concerns among travellers are propelling the market.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the U.K. vaccines market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer
• Valneva SE
• Viatris Inc
• AstraZeneca
• Emergex Vaccines
• GSK plc
• Sanofi
• Merck & Co., Inc.
• Bavarian Nordic A/S
• Prokarium
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In March 2024, AstraZeneca intends to invest £450 million to research, develop, and manufacture vaccines in Speke, Liverpool, a facility that would be operationally net zero with power supplied from renewable energy sources.

Market Segment

This study forecasts revenue at U.K., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United Kingdom Vaccines Market based on the below-mentioned segments:

UK Vaccines Market, By Technology Type

• Inactivated Vaccines
• Toxoid Vaccines
• Recombinant & Conjugate Vaccines
• Live Attenuated Vaccines
• Others

UK Vaccines Market, By Indication  

• Pneumococcal Disease
• Influenza
• Human Papilloma Virus
• Meningococcal Disease
• Rotavirus
• Varicella
• Others

UK Vaccines Market, By End User

• Pediatric
• Adults